BICO has completed the divestment of MatTek and Visikol
1 juli, 17:30
BICO has as of today completed the divestment of MatTek and Visikol to Sartorius, for USD 80m on a cash and debt-free basis, after customary regulatory approval has been obtained. Following transaction costs, net debt and working capital adjustments net proceeds are estimated to amount to USD 77.2m.
The divestment follows the Group’s updated strategy with focus on lab automation and selected workflows. The proceeds from the transaction will be used to strengthen BICO’s balance sheet.
Financial impact will be reported in the interim report for Q2 2025. In BICO’s financial reporting MatTek and Visikol will be treated as discontinued operations from Q2 2025.
For further information on the divestment, please see the press release which was published on April 4, 2025.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above, on July 1, 2025 at 5.30pm CEST.
About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 10,900 publications. Operating through two business areas – Lab Automation and Life Science Solutions – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
Attachments
BICO has completed the divestment of MatTek and Visikol
Ämnen i artikeln
BICO has completed the divestment of MatTek and Visikol
1 juli, 17:30
BICO has as of today completed the divestment of MatTek and Visikol to Sartorius, for USD 80m on a cash and debt-free basis, after customary regulatory approval has been obtained. Following transaction costs, net debt and working capital adjustments net proceeds are estimated to amount to USD 77.2m.
The divestment follows the Group’s updated strategy with focus on lab automation and selected workflows. The proceeds from the transaction will be used to strengthen BICO’s balance sheet.
Financial impact will be reported in the interim report for Q2 2025. In BICO’s financial reporting MatTek and Visikol will be treated as discontinued operations from Q2 2025.
For further information on the divestment, please see the press release which was published on April 4, 2025.
For further information, please contact:
Jacob Thordenberg, CFO, BICO Group AB
Phone: +46 735 34 88 84
E-mail: jt@bico.com
The information was submitted for publication, through the agency of the contact person set out above, on July 1, 2025 at 5.30pm CEST.
About BICO
BICO is a lab automation partner and provider of selected workflows to pharma and biotech. With 48,000+ instruments installed in over 65 countries, BICO products, software, and solutions are found in more than 3,500 laboratories, including the world’s top 20 pharmaceutical companies, and have been cited in over 10,900 publications. Operating through two business areas – Lab Automation and Life Science Solutions – BICO strives towards the vision to enable and automate the life science lab of the future. BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com
Attachments
BICO has completed the divestment of MatTek and Visikol
Ämnen i artikeln
-992x558.webp&w=3840&q=75)
Börsen idag
-992x558.webp&w=3840&q=75)
Börsen idag
-992x558.webp&w=3840&q=75)
.png&w=3840&q=75)
Börsen idag
Börsen idag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
